Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
暂无分享,去创建一个
S. Rosenberg | C. Klebanoff | N. Restifo | P. Spiess | D. Surman | D. Palmer | P. Antony | M. Theoret | D. Heimann | A. Kruisbeek | Zhiya Yu | W. Overwijk | F. Vyth-Dreese | L. Feigenbaum | S. Finkelstein | L. A. de Jong | L. Hwang | T. Dellemijn | L. N. Hwang
[1] Jonathan J. Lewis,et al. A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen1 , 2003, The Journal of Immunology.
[2] E. Wherry,et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.
[3] E. Wherry,et al. Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.
[4] A. Sette,et al. Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1 , 2003, The Journal of Immunology.
[5] L. Chin,et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Nishimura,et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.
[7] S. H. van der Burg,et al. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes , 2002, Immunological reviews.
[8] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[9] S. Rosenberg,et al. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. , 2002, Cancer research.
[10] M. Perales,et al. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. , 2002, Immunity.
[11] Drew M. Pardoll,et al. Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.
[12] D. Speiser,et al. Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance , 2002, The Journal of experimental medicine.
[13] P. Shrikant,et al. Activation-Induced Nonresponsiveness: A Th-Dependent Regulatory Checkpoint in the CTL Response1 , 2002, The Journal of Immunology.
[14] J. Drazba,et al. Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor1 , 2001, The Journal of Immunology.
[15] P. Duray,et al. Neonatal sunburn and melanoma in mice , 2001, Nature.
[16] Rolf M. Zinkernagel,et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.
[17] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[18] A. Houghton,et al. Immunity against cancer: lessons learned from melanoma. , 2001, Current opinion in immunology.
[19] B. Seliger,et al. Characterization of the Major Histocompatibility Complex Class I Deficiencies in B 16 Melanoma Cells 1 , 2001 .
[20] E. Jaffee,et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.
[21] R. Schreiber,et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.
[22] V. Engelhard,et al. Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen , 2000, The Journal of experimental medicine.
[23] N. Restifo,et al. The future of interleukin-2: enhancing therapeutic anticancer vaccines. , 2000, The cancer journal from Scientific American.
[24] S. Rosenberg,et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. , 2000, Journal of immunotherapy.
[25] N. Restifo,et al. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". , 2000, Critical reviews in immunology.
[26] Jonathan J. Lewis,et al. Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.
[27] H. Bien,et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.
[28] R. Offringa,et al. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. , 1999, Cancer research.
[29] Mario Roederer,et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.
[30] B. Moss,et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[31] Yang Liu,et al. Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo , 1999, The Journal of experimental medicine.
[32] P. Coulie,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.
[33] Jonathan J. Lewis,et al. Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.
[34] J. Wolchok,et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. , 1998, The Journal of clinical investigation.
[35] D. Jong,et al. Localization in situ of costimulatory molecules and cytokines in B‐cell non‐Hodgkin’s lymphoma , 1998, Immunology.
[36] B. Moss,et al. gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.
[37] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[38] A. Abbas,et al. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.
[39] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[40] D. Pardoll,et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[41] P. Srivastava,et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.
[42] D. Hanahan,et al. Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.
[43] J. Bluestone,et al. Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.
[44] N. Restifo,et al. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. , 1997, Methods.
[45] S. Rosenberg,et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. , 1997, Journal of immunotherapy.
[46] K. Haas. The Red Star goes to war. , 1997, Veterinary heritage : bulletin of the American Veterinary History Society.
[47] S. Rosenberg,et al. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[48] S. Rosenberg,et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.
[49] S. Rosenberg,et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.
[50] V. Kouskoff,et al. Cassette vectors directing expression of T cell receptor genes in transgenic mice. , 1995, Journal of immunological methods.
[51] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.